GENERAL
Morepen Completes 1st Phase of API, CDMO Expansion Ahead Of Schedule
Morepen Laboratories has completed the first phase of its manufacturing capacity expansion programme ahead of schedule, increasing its installed reactor capacity for active pharmaceutical ingredients (API) and contract development and manufacturing organisation (CDMO) operations from 535 KL to 614 KL. The capacity addition is expected to strengthen Morepen Laboratories’ manufacturing readiness as the company scales […]
CW Bureau
·
Sep 7, 2026
GENERAL
Kwality Pharma Ups FY27 Guidance, Targets ₹1,000 Cr Revenue By FY29
Kwality Pharmaceutical Ltd, which has doubled its turnover to ₹500 crore in three years, has raised its FY27 revenue guidance to over ₹700 crore from ₹650 crore and is targeting more than ₹1,000 crore by FY29. “Over the longer term, we continue to work toward doubling revenue over the next three years, with a goal […]
CW Bureau
·
Aug 10, 2026
GENERAL
Big-Ticket Global Win Shot In The Arm For Morepen’s Ambitions
Morepen Laboratories has secured one of the largest Contract Development and Manufacturing Organisation (CDMO) mandates in its history, winning a multi-year global order valued at around ₹825 crore ($91 million) from a leading international pharmaceutical major. The supplies under the agreement are expected to commence within the next four to five months, with execution scheduled […]
CW Bureau
·
Feb 23, 2026
